Eric Dobmeier is an biotechnology executive with more than 15 years of operating experience. He most recently served as President and Chief Executive Officer of Silverback Therapeutics, a private Seattle-based biotechnology company. Previously, he was Chief Operating Officer of Seattle Genetics, overseeing business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Prior to that, he was with the law firms of Venture Law Group and Heller Ehrman LLP where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric received a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics (Nasdaq: ATRA).